Could a daily pill replace weekly weight‑loss shots? An evergreen take on oral GLP‑1 drugs and combo therapies.

Case Review:

68‑year‑old female, obesity with progressive unintentional weight loss over 6 months after starting an injectable GLP‑1 three months ago; reports increased weakness and one recent near‑fall. Vitals: BP 118/72 mmHg, HR 84 bpm, weight down 9 kg from baseline. Medications: semaglutide 2.4 mg weekly; no diuretics. Pertinent negative: no fever or GI bleeding.

Description:

GLP‑1 drugs reduce appetite and slow gastric emptying, causing weight loss. In older adults, rapid weight loss can include loss of skeletal muscle (lean mass) as well as fat; decreased muscle strength then raises fall risk and functional decline. Test your understanding of GLP-1 pharmacology and its effects on body composition with practicetest.

Clinical Insight:

This pattern—substantial drug‑related weight loss with weakness—is a cue to assess body composition, fall risk, nutrition, and to consider dose adjustment or adding resistance training and protein support to preserve muscle. For a quick reference on evaluating drug-induced sarcopenia in older adults, review studysheet.

Want to lock in the key clinical red flags from this case? Reinforce your recall with flashcards.